This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Astex Pharmaceuticals Announces March 27th Analyst And Investor Day Agenda

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the Agenda for its Annual Analyst and Investor Day webcast, to take place from 10 am to 12 pm ET on Tuesday, March 27th in New York.

Investors and interested parties may access the webcast in the Investor Events section of the Company's website, A webcast replay will be available for 90 days following the live event.

10:00 (5 min.)     Welcome and Introductions    

Timothy L. EnnsSVP, Corporate Communications and Marketing

10:05 (15 min.) Corporate Overview

James S. J. Manuso, Ph.D.Chairman and Chief Executive Officer

10:20 (15 min.) Financial Overview

Michael Molkentin, C.P.A.Chief Financial Officer and Corporate Secretary

10:35 (15 min.)



10:50 (20 min.)

Clinical UpdateSGI-110 & HMAs


Mohammad Azab, M.D.Chief Medical Officer


Jean-Pierre Issa, MDFels Institute of Cancer ResearchTemple University, Philadelphia, PA

11:10 (20 min.) AT 13387 & HSP90 inhibitors

Andrew Wagner, MD, PhDDana Farber Cancer Institute, Boston, MA


11:30 (15 min.)



11:45 (15 min.)

Research & DiscoveryPartnering & Corporate Development


Harren Jhoti, Ph.D.President and Director


Martin BucklandChief Business Officer

12:00 (5 min.) Closing Remarks

James S. J. Manuso, Ph.D.Chairman and Chief Executive Officer

The times listed above are approximate and are subject to change.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs